Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

36.88 +0.12 (+0.33%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gsk Plc ADR

< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
People Needed
If qualified people are not looking for work, they will have to be lured to do so with higher wages. 
Via Talk Markets
Exposures Labor
Why Alector Blasted Higher Today
It's not every day that a small biotech announces a major collaboration deal with a deep-pocketed pharmaceutical giant. 
Via The Motley Fool
Arrowhead Stock Plunges, Alector Stock Surges On Drug News
Arrowhead paused a drug study; Alector teamed up with GlaxoSmithKline to develop two drugs. Arrowhead stock sank, while Alector stock surged. 
Via Investor's Business Daily
GlaxoSmithKline's Board Backs CEO Walmsley After Elliott's Letter For Management Shakeup
GlaxoSmithKline plc (NYSE: GSK) said its board sees Chief Executive Emma Walmsley as the right person to lead its pharmaceutical business after the upcoming split... 
Via Benzinga
ALEC Stock: 12 Things to Know About Alector as GSK News Sends It Rocketing Higher
Alector (ALEC) stock is rocketing higher on Friday after the biotechnology company announced a partnership with GlaxoSmithKline (GSK). 
Via InvestorPlace
Alector Shares Jump On $2.2B Immuno-Neurology Development Pact With GSK
Alector Inc (NASDAQ: ALEC) and GlaxoSmithKline plc (NYSE: GSK) have announced a global collaboration for the development and commercialization of two... 
Via Benzinga
Is a Bigger Shake-Up at GlaxoSmithKline on the Way?
An activist investor seems to be pushing for one. 
Via The Motley Fool
New Month And Half Year
Welcome to H2. In theory, if markets did well in H1 they tend to close the year up. 
Via Talk Markets
Activist Fund Elliott Management Wants GlaxoSmithKline Board Shakeup For 'Years Of Under Management'
Elliott Management has finally made its intentions around GlaxoSmithKline plc (NYSE: GSK) known and calls for changes to rescue GSK from what it called "years... 
Via Benzinga
GlaxoSmithKline's and Vir's Latest COVID Therapy Results: What Investors Should Know
The sample size was small, but the results were impressive. 
Via The Motley Fool
Exposures COVID-19
EC Selects Antibody Therapies, Arthritis Drug As Preferred COVID-19 Meds: Reuters
The European Commission (EC) picked four antibody treatments and a repurposed Eli Lilly And Co's (NYSE: LLY) rheumatoid arthritis drug for an initial... 
Via Benzinga
Exposures COVID-19
Saint Warren
Today the WTI oil price rose further up over 1%. 
Via Talk Markets
AstraZeneca COVID-19 Vaccine Shows Higher Immune Response With Longer Gap, Third Booster Dose
A sub-analysis from the Oxford-led COV001 and COV002 trials with AstraZeneca Plc (NASDAQ: AZN) COVID-19 vaccine induced strong immune responses following... 
Via Benzinga
Exposures COVID-19
Wednesday Is A Normal Day
Meme stocks Gamestop and Torchlight Energy both did share sales to cash in on their share price rises. 
Via Talk Markets
A Look Into GlaxoSmithKline's Debt
Over the past three months, shares of GlaxoSmithKline (NYSE:GSK) increased by 9.84%. Before we understand the importance of debt, let us look at how much debt... 
Via Benzinga
Reconsidered Boom
The US markets tried to repeat the big rise from yesterday, and appears to have succeeded. 
Via Talk Markets
Dual-Antibody Cocktail Shows Effectiveness In COVID-19 Animal Models: Reuters
In mice and hamster study, COVID-19 therapies comprising two types of antibodies were found to be effective against a wide range of COVID-19 variants, Reuters reported ... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 21) Agios Pharmaceuticals, Inc... 
Via Benzinga
GSK- Pfizer's ViiV To Develop 'Ultra-Long-Acting' HIV Drugs With $215M Halozyme Deal
GlaxoSmithKline plc (NYSE: GSK), Pfizer Inc (NYSE: PFE), and Shionogi Limited owned ViiV Healthcare has collaborated with Halozyme... 
Via Benzinga
The First Day Of Summer And Prime Day
The bull is back in business today. 
Via Talk Markets
GlaxoSmithKline CEO Struggling To Get Key Shareholders In Her Favor Amid Pressure From Hedge Fund Activist Elliott Management
GlaxoSmithKline Plc's (NYSE: GSK) CEO Emma Walmsley struggled to win over key shareholders after Elliott Management attracted converts for radical change at the company... 
Via Benzinga
GSK - Vir Biotech's Sotrovimab Reduces Hospitalization, Risk Of Death In Adult COVID-19 Patients
GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced final, confirmatory results from the Phase 3 COMET-ICE evaluating... 
Via Benzinga
Exposures COVID-19
CureVac Stock Plummets After Covid Vaccine Fails In Interim Analysis
CureVac stock plummeted Thursday after its messenger RNA-based Covid vaccine failed in an interim analysis. The vaccine was 47% effective against Covid of any severity. 
Via Investor's Business Daily
Exposures COVID-19
Tesla-Backed CureVac Plunges On Underwhelming COVID-19 Vaccine Efficacy Data
German vaccine developer, CureVac N.V. (NASDAQ: CVAC), may not be as fortunate as its domestic peer BioNTech SE (NASDAQ: BNTX), which along with its... 
Via Benzinga
Exposures COVID-19
GSK: Can This Pharma Giant Sustain Its 5.2% Yield?
GlaxoSmithKline’s free cash flow has been up and down. Over the past three years, it has grown substantially, though this year, it is forecast to drop 18%. 
Via Talk Markets
Continued Uncertainty
Fear of another Fukushima yesterday late in the market day led to a rush out of energy-related shares, which included many without any nuclear risk at all. 
Via Talk Markets
Dreary Day
Another dreary day and a renewed boost for cryptocurrency - and away from the classic inflation hedge, gold. 
Via Talk Markets
IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings
This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Why iTeos Therapeutics Stock Soared Today
The biotech struck a potential $2 billion deal with a pharmaceutical giant. 
Via The Motley Fool
iTeos Therapeutics Stock Surges On $2.1B Development Pact For EOS-448 With GSK
iTeos Therapeutics (NASDAQ: ITOS) and GlaxoSmithKline plc (NYSE: GSK) have agreed to co-develop and co-commercialize EOS-448, an anti-TIGIT monoclonal... 
Via Benzinga
< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.